Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Acetylon snags $100 million upfront cash and acquisition option

05:20 EDT 30 Jul 2013 | thePharmaLetter

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic collaboration for Acetylon's pipeline of selective histone deacetylase (HDAC) inhibitors with $100 million cash upfront and a time-bound optio...

Original Article: Acetylon snags $100 million upfront cash and acquisition option

NEXT ARTICLE

More From BioPortfolio on "Acetylon snags $100 million upfront cash and acquisition option"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story